Virogenomics Biodevelopment, Inc.
Tigard, OR Doing business as Virogenomics Biodevelopment Inc.
- UEI
- SBP8W3KVM9E4
- CAGE
- 7D7U0
- Primary NAICS
- Not on record
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 7320 SW Hunziker St #104, Tigard, OR 97223, USA
- Website
- virogenomics.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Treatment of CNS damage from non-disordered drug use with drhq, a novel regulator of CD74 signaling - project abstract… | National Institute on Drug Abuse | $399,889 | |
| IND-enabling studies and phase i clinical trials to advance CD74-target, drhq, as a treatment for stimulant use disorder… | National Institute on Drug Abuse | $9,889,008 | |
| Immunotherapeutic targeting CD74 as a treatment for stimulant use disorder - project abstract methamphetamine is a… | National Institute on Drug Abuse | $810,668 | |
| Developing novel fibrillin biomarkers for aortic disease | National Heart Lung and Blood Institute | $268,643 | |
| DR?1-MOG as a next-generation immunotherapy for methamphetamine use disorder | National Institute on Drug Abuse | $299,560 |
About Virogenomics Biodevelopment, Inc.
Virogenomics Biodevelopment, Inc., a woman-owned small business based in Tigard, Oregon, is a biopharmaceutical research and development company operating as a federal grant recipient focused on preclinical and clinical-stage immunotherapeutic drug development. The vendor operates exclusively as a grant recipient (100% of recent awards are prime grants); it has no federal contract prime or subcontractor footprint and does not hold positions on government-wide acquisition vehicles or BPAs.
The company's federal capability portfolio centers on designing and advancing CD74-targeted immunotherapeutic compounds for central nervous system disorders and stimulant use disorders. Recent representative work includes a $399,889 Project Grant from the National Institute on Drug Abuse (CFDA 93.279, Drug Use and Addiction Research Programs) awarded June 1, 2026, supporting preclinical research and development of DRHQ, a novel third-generation immunotherapeutic compound targeting CD74 (macrophage migration inhibitory factor receptor) to treat methamphetamine-induced CNS damage through inflammation reduction and cognitive restoration in animal models. A Cooperative Agreement from NIDA (May 15, 2025) funds IND-enabling studies and Phase I clinical trials to advance DRHQ through human safety testing in healthy volunteers and individuals with methamphetamine use disorder, including large-scale manufacturing to support toxicology studies. An earlier Project Grant from NIDA (June 15, 2024) evaluated DRHQ in preclinical animal models of stimulant use disorder, confirming cross-species efficacy in rats and mice.
Customer concentration is heavily concentrated within the National Institutes of Health's National Institute on Drug Abuse, which accounts for four of ten tracked awards (40% of the award count), with secondary support from NIDA's peer institutes within NIH — the National Institute of Allergy and Infectious Diseases and National Cancer Institute. Combined dollars obligated across all tracked awards total $18.8 million. Activity is sparse but recent: one award per year in 2024, 2025, and 2026, following a gap from 2019 to 2023. Two awards carry ultimate completion dates within the next twenty-four months and will face recompete or continuation-renewal decisions in that window.
Quick answers
What is Virogenomics Biodevelopment, Inc.'s UEI?
Virogenomics Biodevelopment, Inc.'s Unique Entity ID (UEI) in SAM.gov is SBP8W3KVM9E4.
What is Virogenomics Biodevelopment, Inc.'s CAGE code?
Virogenomics Biodevelopment, Inc.'s CAGE code is 7D7U0.
Where is Virogenomics Biodevelopment, Inc. located?
Virogenomics Biodevelopment, Inc.'s physical address in SAM.gov is 7320 SW Hunziker St #104, Tigard, OR 97223, USA.
Is Virogenomics Biodevelopment, Inc. registered in SAM.gov?
Virogenomics Biodevelopment, Inc.'s SAM.gov registration expired on August 25, 2026.
What is Virogenomics Biodevelopment, Inc.'s most recent federal award?
Virogenomics Biodevelopment, Inc.'s most recent federal grant award is Treatment of CNS damage from non-disordered drug use with drhq, a novel regulator of CD74 signaling - project abstract… (R41DA064189), from National Institute on Drug Abuse, on June 1, 2026.
On GovTribe
See Virogenomics Biodevelopment, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors